A Combined Heart Pill and Nurse Teaching Program for People After Acute Coronary Syndrome
Tests a combined heart pill plus nurse teaching on taking medicines after acute coronary syndrome.
Key facts
- Who runs it
- Fundacion Epic
- Where
- L'hospitalet De Llobregat, SpainSee the site
- Trial code
- Registry title
- Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 216 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 31 Oct 2027
- Type of study
- Interventional
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults admitted to hospital with acute coronary syndrome (a sudden heart problem with reduced blood flow to the heart). It tests a combined heart pill plus a nurse-led education program.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute coronary syndrome: chest pain suggesting reduced blood flow to the heart, with heart tracing (ECG) changes and/or raised high-sensitivity troponin (a blood marker of heart damage).
- Biomarker or test result
- High-sensitivity troponin above the laboratory reference level, or heart tracing (ECG) changes, as part of the diagnosis.
Main reasons for not taking part
- Cannot take any component of the polypill (combined heart pill)
- Refuses or cannot give informed consent
- Cannot complete the clinical follow-up
- Lives in a long-term care facility or nursing home at the start or during the one-year follow-up
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult patients admitted for acute coronary syndrome (ACS) at the study centers between September 2024 and September 2026. ACS will be defined as chest pain suggestive of ischemia accompanied by electrocardiographic changes indicative of myocardial ischemia (T-wave inversion, ST-segment elevation or depression, new onset left bundle branch block) and/or high-sensitivity troponin elevation above the laboratory reference threshold
Who cannot take part
- Contraindication to any of the components of the polypill
- Refusal or inability to provide informed consent
- Inability to complete clinical follow-up
- Patients admitted to long-term care facilities or nursing homes at the time of inclusion and/or during the one-year follow-up
Where in Spain
- Bellvitge University HospitalL'hospitalet De Llobregat, SpainNot yet recruiting
About the trial
What the trial wants to find out
To evaluate, through a randomized controlled trial, the potential additive impact of prescribing the cardiovascular polypill at hospital discharge combined with the implementation of a nurse-led education program on therapeutic adherence one year after admission, in patients with acute coronary syndrome (ACS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study
- Plain-language title
- A Combined Heart Pill and Nurse Teaching Program for People After Acute Coronary SyndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 March 2026